Table 3. Rosuvastatin Camparator-Controlled Trials in Patients with Primary Hypercholesterolemia
|
Study
|
N
|
Treatments
(dose/day) |
Results
|
|
|
%
of LDL-Cholesterol Reduction from Baseline
|
%
of Patients
Achieving ATP-II or -III Targets |
|||
| Olsson
et al. 200114 Randomized, open-label, comparator- and placebo-controlled trial 6 weeks |
142
|
Rosuvastatin 1-40 mg |
34-65
|
N/A
|
| Atorvastatin 10 mg |
44
|
|||
| Atorvastatin 80 mg |
59
|
|||
| Placebo |
-3.6
|
|||
| Paoletti
et al. 200115 Randomized, double-blind, multi-center, comparatory-controlled trial 12 weeks |
502 |
Rosuvastatin 5 mg |
42
|
71
|
| Rosuvastatin 10 mg |
49
|
87
|
||
| Pravastatin 20 mg |
28
|
53
|
||
| Simvastatin 20 mg |
37
|
64
|
||
| Brown
et al. 200216 Randomized, double-blind, multi-center, comparator-controlled trial |
Fixed
Dose Period 12 wks 477 |
Rosuvastatin 5 mg |
39
|
80
|
| Rosuvastatin 10 mg |
47
|
90
|
||
| Pravastatin 20 mg |
27
|
53
|
||
| Simvastatin 20 mg |
35
|
69
|
||
| Dose
Titration Period 52 wks 477 |
Rosuvastatin 5-80 mg |
42
|
88
|
|
| Rosuvastatin 10-80 mg |
48
|
88
|
||
| Pravastatin 40 mg |
32
|
60
|
||
| Simvastatin 80 mg |
38
|
73
|
||
| Olsson
et al. 200217 Randomized, double-blind, multi-center, comparator-controlled trial |
Fixed
Dose Period 12 wks 412 |
Rosuvastatin 5 mg |
46
|
86
|
| Rosuvastatin 10 mg |
50
|
73
|
||
| Atorvastatin 10 mg |
39
|
86
|
||
| Dose
Titration Period 52 wks 412 |
Rosuvastatin 5-80 mg |
47
|
88
|
|
| Rosuvastatin 10-80 mg |
53
|
98
|
||
| Atorvastatin 80 mg |
44
|
87
|
||
|
Davidson et al.
200218 |
516 |
Rosuvastatin 5 mg |
40
|
84
|
| Rosuvastatin 10 mg |
43
|
82
|
||
| Atorvastatin 10 mg |
35
|
72
|
||
| Placebo |
0
|
12
|
||
| Adapted from Olsson AG et al. Am J Cardiol 2001; 88:504-8, Paoletti R et al. J Cardiovasc Risk 2001:8:383-90, Brown WV et al. Am Heart J 2002; 144: 1036-43, Olsson AG et al. Am Heart J 2002;144:1044-51, Davidson M et al. Am J Cardiol 2002;89:268-75. |
Click Here to Return to Article